Diagnostic value of plasma phosphorylated tau181 in Alzheimer's disease and frontotemporal lobar degeneration.
Aged
Alzheimer Disease
/ blood
Amyloid
/ metabolism
Amyloid beta-Peptides
/ blood
Biomarkers
/ blood
Cognition
Female
Frontotemporal Lobar Degeneration
/ blood
Gray Matter
/ diagnostic imaging
Heterozygote
Humans
Male
Middle Aged
Mutation
/ genetics
Neurofilament Proteins
/ blood
Phosphorylation
Positron-Emission Tomography
Severity of Illness Index
tau Proteins
/ blood
Journal
Nature medicine
ISSN: 1546-170X
Titre abrégé: Nat Med
Pays: United States
ID NLM: 9502015
Informations de publication
Date de publication:
03 2020
03 2020
Historique:
received:
19
07
2019
accepted:
10
01
2020
pubmed:
4
3
2020
medline:
9
4
2020
entrez:
4
3
2020
Statut:
ppublish
Résumé
With the potential development of new disease-modifying Alzheimer's disease (AD) therapies, simple, widely available screening tests are needed to identify which individuals, who are experiencing symptoms of cognitive or behavioral decline, should be further evaluated for initiation of treatment. A blood-based test for AD would be a less invasive and less expensive screening tool than the currently approved cerebrospinal fluid or amyloid β positron emission tomography (PET) diagnostic tests. We examined whether plasma tau phosphorylated at residue 181 (pTau181) could differentiate between clinically diagnosed or autopsy-confirmed AD and frontotemporal lobar degeneration. Plasma pTau181 concentrations were increased by 3.5-fold in AD compared to controls and differentiated AD from both clinically diagnosed (receiver operating characteristic area under the curve of 0.894) and autopsy-confirmed frontotemporal lobar degeneration (area under the curve of 0.878). Plasma pTau181 identified individuals who were amyloid β-PET-positive regardless of clinical diagnosis and correlated with cortical tau protein deposition measured by
Identifiants
pubmed: 32123386
doi: 10.1038/s41591-020-0762-2
pii: 10.1038/s41591-020-0762-2
pmc: PMC7101073
mid: NIHMS1549223
doi:
Substances chimiques
Amyloid
0
Amyloid beta-Peptides
0
Biomarkers
0
Neurofilament Proteins
0
neurofilament protein L
0
tau Proteins
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
387-397Subventions
Organisme : NIA NIH HHS
ID : P50 AG023501
Pays : United States
Organisme : NIA NIH HHS
ID : K24 AG045333
Pays : United States
Organisme : NIA NIH HHS
ID : U24 AG021886
Pays : United States
Organisme : NIA NIH HHS
ID : P50 AG016574
Pays : United States
Organisme : NIA NIH HHS
ID : K24 AG053435
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG038791
Pays : United States
Organisme : NIA NIH HHS
ID : U19 AG063911
Pays : United States
Organisme : NIA NIH HHS
ID : RF1 AG050967
Pays : United States
Organisme : NIA NIH HHS
ID : P01 AG019724
Pays : United States
Organisme : NIA NIH HHS
ID : P01 AG066597
Pays : United States
Organisme : NIMH NIH HHS
ID : R01 MH120794
Pays : United States
Organisme : NIA NIH HHS
ID : K23 AG059888
Pays : United States
Organisme : NIA NIH HHS
ID : K08 AG052648
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG062268
Pays : United States
Organisme : NIA NIH HHS
ID : U01 AG045390
Pays : United States
Organisme : NINDS NIH HHS
ID : U54 NS092089
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG045611
Pays : United States
Organisme : NIA NIH HHS
ID : T32 AG023481
Pays : United States
Organisme : NIA NIH HHS
ID : P30 AG062422
Pays : United States
Investigateurs
Leah Forsberg
(L)
David S Knopman
(DS)
Neill Graff-Radford
(N)
Murray Grossman
(M)
Edward H Huey
(EH)
Chiadi Onyike
(C)
Daniel Kaufer
(D)
Erik Roberson
(E)
Nupur Ghoshal
(N)
Sandra Weintraub
(S)
Brian Appleby
(B)
Irene Litvan
(I)
Diana Kerwin
(D)
Mario Mendez
(M)
Yvette Bordelon
(Y)
Giovanni Coppola
(G)
Eliana Marisa Ramos
(EM)
M Carmela Tartaglia
(MC)
Ging-Yuek Hsiung
(GY)
Ian MacKenzie
(I)
Kimiko Domoto-Reilly
(K)
Tatiana Foroud
(T)
Bradford C Dickerson
(BC)
Commentaires et corrections
Type : CommentIn
Type : CommentIn
Références
Nature News Round-up. Swine flu snipers, Alzheimer’s drug push and Google’s latest gaming bot. Nature 574 602–603 (2019).
Rabinovici, G. D. et al. Association of amyloid positron emission tomography with subsequent change in clinical management among Medicare beneficiaries with mild cognitive impairment or dementia. J. Am. Med. Assoc. 94158, 1286–1294 (2019).
doi: 10.1001/jama.2019.2000
Landau, S. M. et al. Comparing positron emission tomography imaging and cerebrospinal fluid measurements of β-amyloid. Ann. Neurol. 74, 826–836 (2013).
doi: 10.1002/ana.23908
pubmed: 23536396
pmcid: 23536396
Palmqvist, S. et al. Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease. Neurology 85, 1240–1249 (2015).
doi: 10.1212/WNL.0000000000001991
pubmed: 26354982
pmcid: 26354982
Rabinovici, G. D. & Miller, B. L. Frontotemporal lobar degeneration: epidemiology, pathophysiology, diagnosis and management. CNS Drugs 24, 375–398 (2010).
doi: 10.2165/11533100-000000000-00000
pubmed: 20369906
pmcid: 20369906
Bahia, V. S., Takada, L. T. & Deramecourt, V. Neuropathology of frontotemporal lobar degeneration: a review. Dement. Neuropsychol. 7, 19–26 (2013).
doi: 10.1590/S1980-57642013DN70100004
pubmed: 29213815
pmcid: 29213815
Buerger, K. et al. CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer’s disease. Brain 129, 3035–3041 (2006).
doi: 10.1093/brain/awl269
pubmed: 17012293
pmcid: 17012293
Tapiola, T. et al. Cerebrospinal fluid β-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch. Neurol. 66, 382–389 (2009).
doi: 10.1001/archneurol.2008.596
pubmed: 19273758
pmcid: 19273758
Schöll, M. et al. Biomarkers for tau pathology. Mol. Cell. Neurosci. 97, 18–33 (2019).
doi: 10.1016/j.mcn.2018.12.001
pubmed: 30529601
pmcid: 30529601
Marquié, M. et al. Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue. Ann. Neurol. 78, 787–800 (2015).
doi: 10.1002/ana.24517
pubmed: 26344059
pmcid: 26344059
Ossenkoppele, R. et al. Discriminative accuracy of [18F]flortaucipir positron emission tomography for Alzheimer disease vs other neurodegenerative disorders. J. Am. Med. Assoc. 320, 1151–1162 (2018).
doi: 10.1001/jama.2018.12917
Bacioglu, M. et al. Neurofilament light chain in blood and CSF as marker of disease progression in mouse models and in neurodegenerative diseases. Neuron 91, 56–66 (2016).
doi: 10.1016/j.neuron.2016.05.018
pubmed: 27292537
pmcid: 27292537
Meeter, L. H., Kaat, L. D., Rohrer, J. D. & Van Swieten, J. C. Imaging and fluid biomarkers in frontotemporal dementia. Nat. Rev. Neurol. 13, 406–419 (2017).
doi: 10.1038/nrneurol.2017.75
pubmed: 28621768
pmcid: 28621768
Khalil, M. et al. Neurofilaments as biomarkers in neurological disorders. Nat. Rev. Neurol. 14, 577–589 (2018).
doi: 10.1038/s41582-018-0058-z
pubmed: 30171200
pmcid: 30171200
Meeter, L. H. H. et al. Clinical value of neurofilament and phospho-tau/tau ratio in the frontotemporal dementia spectrum. Neurology 90, e1231–e1239 (2018).
doi: 10.1212/WNL.0000000000005261
pubmed: 29514947
pmcid: 29514947
Ljubenkov, P. A. et al. Cerebrospinal fluid biomarkers predict frontotemporal dementia trajectory. Ann. Clin. Transl. Neurol. 5, 1250–1263 (2018).
doi: 10.1002/acn3.643
pubmed: 30349860
pmcid: 30349860
Scherling, C. S. et al. CSF neurofilament concentration reflects disease severity in frontotemporal degeneration. Ann. Neurol. 75, 116–126 (2014).
doi: 10.1002/ana.24052
pubmed: 24242746
pmcid: 24242746
Rojas, J. C. et al. CSF neurofilament light chain and phosphorylated tau 181 predict disease progression in PSP. Neurology 90, e273–e281 (2018).
doi: 10.1212/WNL.0000000000004859
pubmed: 29282336
pmcid: 29282336
Rohrer, J. D. et al. Serum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia. Neurology 87, 1329–1336 (2016).
doi: 10.1212/WNL.0000000000003154
pubmed: 27581216
pmcid: 27581216
Steinacker, P. et al. Serum neurofilament light chain in behavioral variant frontotemporal dementia. Neurology 91, e1390–e1401 (2018).
doi: 10.1212/WNL.0000000000006318
pubmed: 30209235
pmcid: 30209235
Bridel, C., van Wieringen, W. N. & Zetterberg, H. Diagnostic value of cerebrospinal fluid neurofilament light protein in neurology: a systematic review and meta-analysis. JAMA Neurol. 76, 1035–1048 (2019).
doi: 10.1001/jamaneurol.2019.1534
Preische, O. et al. Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer’s disease. Nat. Med. 25, 277–283 (2019).
doi: 10.1038/s41591-018-0304-3
pubmed: 30664784
pmcid: 30664784
Mattsson, N., Cullen, N. C., Andreasson, U., Zetterberg, H. & Blennow, K. Association between longitudinal plasma neurofilament light and neurodegeneration in patients with Alzheimer disease. JAMA Neurol. 76, 791–799 (2019).
doi: 10.1001/jamaneurol.2019.0765
pubmed: 31009028
pmcid: 31009028
Nakamura, A. et al. High performance plasma amyloid-β biomarkers for Alzheimer’s disease. Nature 554, 249–254 (2018).
doi: 10.1038/nature25456
pubmed: 29420472
pmcid: 29420472
Ovod, V. et al. Amyloid β concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis. Alzheimers Dement. 13, 841–849 (2017).
doi: 10.1016/j.jalz.2017.06.2266
pubmed: 5567785
pmcid: 5567785
Janelidze, S. et al. Plasma β-amyloid in Alzheimer’s disease and vascular disease. Sci. Rep. 6, 26801 (2016).
doi: 10.1038/srep26801
pubmed: 27241045
pmcid: 27241045
Mielke, M. M. et al. Association of plasma total tau level with cognitive decline and risk of mild cognitive impairment or dementia in the Mayo Clinic study on aging. JAMA Neurol. 74, 1073–1080 (2017).
doi: 10.1001/jamaneurol.2017.1359
pubmed: 28692710
pmcid: 28692710
Mattsson, N. et al. Plasma tau in Alzheimer disease. Neurology 87, 1827–1835 (2016).
doi: 10.1212/WNL.0000000000003246
pubmed: 27694257
pmcid: 27694257
Chen, Z. et al. Learnings about the complexity of extracellular tau aid development of a blood-based screen for Alzheimer’s disease. Alzheimers Dement. 15, 487–496 (2018).
doi: 10.1016/j.jalz.2018.09.010
pubmed: 30419228
pmcid: 30419228
Hampel, H. et al. Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic. Nat. Rev. Neurol. 14, 639–652 (2018).
doi: 10.1038/s41582-018-0079-7
pubmed: 30297701
pmcid: 30297701
Mielke, M. M. et al. Plasma phospho-tau181 increases with Alzheimer’s disease clinical severity and is associated with tau- and amyloid-positron emission tomography. Alzheimer’s Dement. 14, 989–997 (2018).
doi: 10.1016/j.jalz.2018.02.013
Ghetti, B. et al. Frontotemporal dementia caused by microtubule-associated protein tau gene (MAPT) mutations: a chameleon for neuropathology and neuroimaging. Neuropathol. Appl. Neurobiol. 41, 24–46 (2015).
doi: 10.1111/nan.12213
pubmed: 25556536
pmcid: 25556536
Maass, A. et al. NeuroImage comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer’ s disease. Neuroimage 157, 448–463 (2017).
doi: 10.1016/j.neuroimage.2017.05.058
pubmed: 5814575
pmcid: 5814575
Braak, H. & Braak, E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol. 82, 239–259 (1991).
doi: 10.1007/BF00308809
Braak, H., Thal, D. R., Ghebremedhin, E. & Del Tredici, K. Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. J. Neuropathol. Exp. Neurol. 70, 960–969 (2011).
doi: 10.1097/NEN.0b013e318232a379
pubmed: 22002422
pmcid: 22002422
Rabinovici, G. D. et al. Distinct MRI atrophy patterns in autopsy-proven Alzheimer’s disease and frontotemporal lobar degeneration. Am. J. Alzheimers Dis. Other Demen. 22, 474–488 (2007).
doi: 10.1177/1533317507308779
pubmed: 18166607
pmcid: 18166607
Halabi, C. et al. Patterns of striatal degeneration in frontotemporal dementia. Alzheimer Dis. Assoc. Disord. 27, 74–83 (2013).
doi: 10.1097/WAD.0b013e31824a7df4
pubmed: 22367382
pmcid: 22367382
Doraiswamy, P. M. et al. Florbetapir F 18 amyloid PET and 36-month cognitive decline: a prospective multicenter study. Mol. Psychiatry 19, 1044–1051 (2014).
doi: 10.1038/mp.2014.9
pubmed: 24614494
pmcid: 24614494
Clark, C. M. et al. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study. Lancet Neurol. 11, 669–678 (2012).
doi: 10.1016/S1474-4422(12)70142-4
pubmed: 22749065
pmcid: 22749065
La Joie, R. et al. Multisite study of the relationships between antemortem [
doi: 10.1016/j.jalz.2018.09.001
pubmed: 30347188
pmcid: 30347188
Rabinovici, G. D. et al. Amyloid vs FDG-PET in the differential diagnosis of AD and FTLD. Neurology 77, 2034–2042 (2011).
doi: 10.1212/WNL.0b013e31823b9c5e
pubmed: 22131541
pmcid: 22131541
Knopman, D. S. et al. Entorhinal cortex tau, amyloid-β, cortical thickness and memory performance in non-demented subjects. Brain 142, 1148–1160 (2019).
doi: 10.1093/brain/awz025
pubmed: 30759182
pmcid: 30759182
van Harten, A. C. et al. Tau and p-tau as CSF biomarkers in dementia: a meta-analysis. Clin. Chem. Lab. Med. 49, 353–366 (2011).
doi: 10.1515/CCLM.2011.086
pubmed: 21342021
pmcid: 21342021
Rivero-Santana, A. et al. Cerebrospinal fluid biomarkers for the differential diagnosis between Alzheimer’s disease and frontotemporal lobar degeneration: systematic review, HSROC analysis, and confounding factors. J. Alzheimers Dis. 55, 625–644 (2017).
doi: 10.3233/JAD-160366
pubmed: 27716663
pmcid: 27716663
del Campo, M. et al. Novel CSF biomarkers to discriminate FTLD and its pathological subtypes. Ann. Clin. Transl. Neurol. 5, 1163–1175 (2018).
doi: 10.1002/acn3.629
pubmed: 30349851
pmcid: 30349851
Jones, D. T. et al. In vivo
doi: 10.1212/WNL.0000000000005117
pubmed: 29440563
pmcid: 29440563
Smith, R. et al. 18F-AV-1451 tau PET imaging correlates strongly with tau neuropathology in MAPT mutation carriers. Brain 139, 2372–2379 (2016).
doi: 10.1093/brain/aww163
pubmed: 4995360
pmcid: 4995360
La Joie, R. et al. Associations between [18 F]AV1451 tau PET and CSF measures of tau pathology in a clinical sample. Neurology 90, e282–e290 (2018).
doi: 10.1212/WNL.0000000000004860
pubmed: 29282337
pmcid: 29282337
Pontecorvo, M. J. et al. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition. Brain 140, 748–763 (2017).
pubmed: 28077397
pmcid: 28077397
Jack, C. R. et al. Longitudinal tau PET in ageing and Alzheimer’s disease. Brain 141, 1517–1528 (2018).
doi: 10.1093/brain/awy059
pubmed: 29538647
pmcid: 29538647
Palmqvist, S. et al. Performance of fully automated plasma assays as screening tests for Alzheimer disease-related β-amyloid status. JAMA Neurol. 76, 1060–1069 (2019).
doi: 10.1001/jamaneurol.2019.1632
pubmed: 6593637
pmcid: 6593637
Lee, S. E. et al. Clinicopathological correlations in corticobasal degeneration. Ann. Neurol. 70, 327–340 (2011).
doi: 10.1002/ana.22424
pubmed: 21823158
pmcid: 21823158
McKhann, G. M. et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers. Dement. 7, 263–269 (2011).
doi: 10.1016/j.jalz.2011.03.005
pubmed: 21514250
pmcid: 21514250
Albert, M. S. et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers. Dement. 7, 270–279 (2011).
doi: 10.1016/j.jalz.2011.03.008
pubmed: 21514249
pmcid: 21514249
Hoglinger, G. U. et al. Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria HHS public access author manuscript. Mov. Disord. 32, 853–864 (2017).
doi: 10.1002/mds.26987
pubmed: 5516529
pmcid: 5516529
Rascovsky, K. et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain 134, 2456–2477 (2011).
doi: 10.1093/brain/awr179
pubmed: 21810890
pmcid: 21810890
Gorno-Tempini, M. L. et al. Classification of primary progressive aphasia and its variants. Neurology 76, 1006–1014 (2011).
doi: 10.1212/WNL.0b013e31821103e6
pubmed: 21325651
pmcid: 21325651
Lynch, C. A. et al. The clinical dementia rating sum of box score in mild dementia. Dement. Geriatr. Cogn. Disord. 21, 40–43 (2006).
doi: 10.1159/000089218
pubmed: 16254429
pmcid: 16254429
Folstein, M. F., Folstein, S. E. & McHugh, P. R. ‘Mini-mental state’. A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 12, 189–198 (1975).
doi: 10.1016/0022-3956(75)90026-6
pubmed: 1202204
pmcid: 1202204
Kramer, J. H. et al. Distinctive neuropsychological patterns in frontotemporal dementia, semantic dementia, and Alzheimer disease. Cogn. Behav. Neurol. 16, 211–218 (2003).
doi: 10.1097/00146965-200312000-00002
pubmed: 14665820
pmcid: 14665820
D’Elia, L. F., Satz, P., Uchiyama, C. & White, T. Color Trails Test. Professional Manual (Psychological Assessment Resources, 1996).
Heaton, R., Miller, S., Taylor, M. & Grant, I. Revised Comprehensive Norms for an Expanded Halstead-Reitan Battery: Demographically Adjusted Neuropsychological Norms for African American and Caucasian Adults (Psychological Assessment Resources, 2004).
Kaplan, E., Goodglass, H. & Weintraub, S. Boston Naming Test (Lea & Febiger, 1983).
Yesavage, J. A. et al. Development and validation of a geriatric depression screening scale: a preliminary report. J. Psychiatr. Res. 17, 37–49 (1982).
doi: 10.1016/0022-3956(82)90033-4
pubmed: 7183759
pmcid: 7183759
Pfeffer, R. I., Kurosaki, T. T., Harrah, C. H. J., Chance, J. M. & Filos, S. Measurement of functional activities in older adults in the community. J. Gerontol. 37, 323–329 (1982).
doi: 10.1093/geronj/37.3.323
pubmed: 7069156
pmcid: 7069156
Schwab, R. & England, A. in Third Symposium on Parkinson’s Disease (eds Billingham, F. H. & Donaldson, M. C.) (Churchill Livingstone, 1969).
Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. B 57, 289–300 (1995).
Youden, W. J. Index for rating diagnostic tests. Cancer 3, 32–35 (1950).
doi: 10.1002/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3
pubmed: 15405679
pmcid: 15405679
Alzheimer’s Disease Neuroimaging Initiative (ADNI). ADNI2 Procedures Manual (2010). https://adni.loni.usc.edu/wp-content/uploads/2008/07/adni2-procedures-manual.pdf
Ashburner, J. & Friston, K. J. Unified segmentation. Neuroimage 26, 839–851 (2005).
doi: 10.1016/j.neuroimage.2005.02.018
pubmed: 15955494
pmcid: 15955494
Malone, I. B. et al. Accurate automatic estimation of total intracranial volume: a nuisance variable with less nuisance. Neuroimage 104, 366–372 (2015).
doi: 10.1016/j.neuroimage.2014.09.034
pubmed: 25255942
pmcid: 25255942
Ashburner, J. & Friston, K. J. NeuroImage diffeomorphic registration using geodesic shooting and Gauss–Newton optimisation. Neuroimage 55, 954–967 (2011).
doi: 10.1016/j.neuroimage.2010.12.049
pubmed: 21216294
pmcid: 21216294
Southekal, S. et al. Flortaucipir F18 quantitation using parametric estimation of reference signal intensity. J. Nucl. Med. 59, 944–951 (2018).
doi: 10.2967/jnumed.117.200006
pubmed: 29191858
pmcid: 29191858
Devous, M. D. et al. Test–retest reproducibility for the tau PET imaging agent flortaucipir F 18. J. Nucl. Med. 59, 937–943 (2018).
doi: 10.2967/jnumed.117.200691
pubmed: 29284675
pmcid: 29284675
Villeneuve, S. et al. Existing Pittsburgh Compound-B positron emission tomography thresholds are too high: statistical and pathological evaluation. Brain 138, 2020–2033 (2015).
doi: 10.1093/brain/awv112
pubmed: 25953778
pmcid: 25953778
Xia, M., Wang, J. & He, Y. BrainNet Viewer: a network visualization tool for human brain connectomics. PLoS One 8, e68910 (2013).
doi: 10.1371/journal.pone.0068910
pubmed: 23861951
pmcid: 23861951